ShRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance by Jamshid S. Khorashad, Anna M.

Slides:



Advertisements
Similar presentations
by Kevin J. Paavola, Harwin Sidik, J
Advertisements

Blockade of osteopontin reduces alloreactive CD8 + T cell– mediated graft-versus-host disease by Fang Zhao, Yi Zhang, Hao Wang, Min Jin, Shan He, Yufang.
Finding Cancer Genes.
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology by Tomas Radivoyevitch, Lynn Hlatky, Julian Landaw, and Rainer K. Sachs Blood.
The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo by Vicky Louise Morrison, Matthew MacPherson,
Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes by Joseph C. Mudd, Patrick Murphy, Maura Manion, Robert Debernardo,
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study by David M.
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.
SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo by Ilze Bot, Jian Guo, Miranda Van Eck,
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,
Do HSCs divide asymmetrically?
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
by Dai Chida, Osamu Miura, Akihiko Yoshimura, and Atsushi Miyajima
Imatinib and ABCG2: who controls whom?
“Vitamin hypothesis”: explanation for allergy increase?
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,
Positioning NK-κB in multiple myeloma
by Venetia Bigley, Laura E. Spence, and Matthew Collin
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
by Ji-Long Chen, Andre Limnander, and Paul B. Rothman
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
by Zhenping Zhu Blood Volume 108(6): September 15, 2006
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
Lytic Replication of Epstein-Barr Virus in the Peripheral Blood: Analysis of Viral Gene Expression in B Lymphocytes During Infectious Mononucleosis and.
Tax fingerprint in adult T-cell leukemia
Rethinking bioactivity of FLT3 inhibitors
Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Luis A. Carvajal, Ulrich Steidl  Cell Stem Cell 
Fusion genes in cord blood
An Unusual Cause of Abdominal Pain in Sickle Cell Disease
Impaired negative regulation of homeostatically proliferating T cells
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells by Tomohiko Tamura, Hee Jeong Kong, Chainarong Tunyaplin,
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph.
Ph+ ALL: drawing strength from a benign past
Lymphoma spread? Target CD47-SIRPα!
Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.
Complex interactions between B cells and dendritic cells
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,
Volume 26, Issue 3, Pages (September 2014)
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors by Yu-Ting Chang, Daniela Hernandez,
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Src kinases mediate TSP-1 inhibition of AC and PKA activity.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Attacking Cancer at Its Root
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Patient Tregs express normal levels of suppression.
Although equivalent experimental systems have been employed in a variety of assessments to determine BCR-ABL1 kinase domain mutation sensitivity on the.
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Cold agglutinin disease
Presentation transcript:

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance by Jamshid S. Khorashad, Anna M. Eiring, Clinton C. Mason, Kevin C. Gantz, Amber D. Bowler, Hannah M. Redwine, Fan Yu, Ira L. Kraft, Anthony D. Pomicter, Kimberly R. Reynolds, Anthony J. Iovino, Matthew S. Zabriskie, William L. Heaton, Srinivas K. Tantravahi, Michael Kauffman, Sharon Shacham, Alex Chenchik, Kyle Bonneau, Katharine S. Ullman, Thomas O’Hare, and Michael W. Deininger Blood Volume 125(11): March 12, 2015 ©2015 by American Society of Hematology

K562R and AR230R cells are resistant to imatinib despite inhibition of BCR-ABL1 kinase. Jamshid S. Khorashad et al. Blood 2015;125: ©2015 by American Society of Hematology

Experimental design and reproducibility. Jamshid S. Khorashad et al. Blood 2015;125: ©2015 by American Society of Hematology

Validation of selected candidates from the lentiviral screen. Jamshid S. Khorashad et al. Blood 2015;125: ©2015 by American Society of Hematology

Cytoplasmic RAN contributes to BCR-ABL1 kinase-independent TKI resistance. Jamshid S. Khorashad et al. Blood 2015;125: ©2015 by American Society of Hematology

Ectopic expression of RanGAP confers resistance to imatinib. Jamshid S. Khorashad et al. Blood 2015;125: ©2015 by American Society of Hematology

Enhanced RAN/XPO1 shuttling activity is associated with enhanced levels of cytoplasmic SET in TKI-resistant CML cell lines. Jamshid S. Khorashad et al. Blood 2015;125: ©2015 by American Society of Hematology

Inhibition of RAN/XPO1 impairs survival of CML but not normal CD34+ cord blood cells. Jamshid S. Khorashad et al. Blood 2015;125: ©2015 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.